查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球胰島素輸液幫浦市場 -2023-2030
市場調查報告書
商品編碼
1374789

全球胰島素輸液幫浦市場 -2023-2030

Global Insulin Infusion Pumps Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

胰島素輸注幫浦是小型電腦化設備。胰島素幫浦可以幫助糖尿病患者方便地管理血糖。這些小型設備在特定時間內提供一定劑量的胰島素。許多人發現胰島素幫浦比胰島素筆注射等其他設備更靈活。胰島素幫浦不必是永久性的，可以隨時切換到另一種胰島素管理方法。

眾所周知，胰島素幫浦可以提供自由和靈活性的生活方式。所有第 1 型糖尿病患者和一些第 2 型糖尿病患者在餘生都需要某種類型的胰島素注射選擇，這些胰島素幫浦可以讓糖尿病治療變得更加容易。劑量透過稱為導管的軟性塑膠管輸送。在小針的幫助下，將導管穿過皮膚插入脂肪組織並用膠帶固定到位。管/針組合稱為輸液器。

市場動態：促進因素

越來越多採用先進的胰島素輸注泵

先進胰島素輸注幫浦的日益普及預計將在預測期內推動市場發展。胰島素輸注幫浦的進步有助於更好地治療糖尿病，進而改善患者的治療效果。例如，2022年3月8日，美敦力公司的全資子公司India Medtronic Private Limited在印度推出了MiniMed 780G系統。

MiniMed 780G系統是下一代閉迴路胰島素幫浦系統，用於治療7至80歲族群的第一型糖尿病。該系統利用該公司最先進的 SmartGuard 技術，每五分鐘自動輸送基礎胰島素和校正推注，幫助糖尿病患者更輕鬆地避免情緒高漲和低谷。

此外，胰島素輸注幫浦比其他設備具有更大的優勢，這些幫浦的進步有助於控制和管理胰島素輸注。先進的輸液幫浦提供更精確和持續的胰島素輸送，可以顯著改善血糖控制。這可以為糖尿病患者帶來更好的長期健康結果並減少併發症。

例如，2023年2月14日，EOFlow Co.在阿拉伯聯合大公國推出了其無管、穿戴式、拋棄式胰島素幫浦「EOPatch」。在阿拉伯聯合大公國，可以使用全新的 Narsha 應用程式直接透過 Android 和 iOS 智慧型手機透過 EOPatch 控制和管理胰島素輸注。

此外，監管部門的批准增加了患者對新型先進設備開發的信任。例如，2022 年 2 月 16 日，領先的胰島素輸送和糖尿病技術公司 Tandem Diabetes Care, Inc. 發布了美國食品和藥物管理局 (FDA) 批准的 t : slim X2 胰島素泵的推注胰島素劑量，使用t ：連接行動應用程式。這是首款獲得 FDA 批准的智慧型手機應用程式，能夠在 iOS 和 Android 作業系統上啟動胰島素傳輸。

此外，糖尿病盛行率的增加、FDA 批准的增加、臨床試驗的增加、新型設備開發的意識增強和技術進步預計將在預測期內推動市場發展。

限制

與設備相關的併發症、胰島素輸注幫浦的高成本、與設備相關的技術問題以及替代治療方案的存在等因素預計將阻礙市場。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按組件分類
  • 按應用程式片段
  • 最終使用者的片段
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 越來越多採用先進的胰島素輸注泵
    • 限制
      • 與設備相關的併發症
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 管道分析
  • 未滿足的需求
  • 專利分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按組件

  • 胰島素幫浦
  • 點滴器
  • 水庫

第 8 章：按應用

  • I 型糖尿病
  • II型糖尿病

第 9 章：最終用戶

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Medtronic plc
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • Ascensia Diabetes Care Holdings AG
  • Ypsomed AG
  • F. Hoffmann-La Roche Ltd.
  • Shinmyung Mediyes CO., LTD.
  • Abbott Laboratories
  • SOOIL Developments Co., Ltd
  • Smiths Group plc

第 13 章：附錄

簡介目錄
Product Code: MD7199

Overview

Insulin infusion pumps are small and computerized devices. Insulin pumps can help diabetes patients conveniently manage their blood sugar. These small devices deliver doses of insulin at specific times. Many people find that insulin pumps are a more flexible option than other devices like insulin pen injections. Insulin pumps don't have to be permanent and can switch to another insulin management method at any time.

Insulin pumps are known to offer lifestyle freedom and flexibility. All people with Type 1 diabetes and some people with Type 2 diabetes will need some type of insulin injection option for the rest of their lives, these insulin pumps can make diabetes treatment more easier. Doses are delivered through a flexible plastic tube known as a catheter. With the aid of a small needle, the catheter is inserted through the skin into the fatty tissue and is taped in place. The tube/needle combination is called an infusion set.

Market Dynamics: Drivers

Increasing adoption of advanced insulin infusion pumps

The increasing adoption of advanced insulin infusion pumps is expected to drive the market over the forecast period. The advancements in insulin infusion pumps helps in the better treatment of diabetes, resulting in better patient outcomes. For instance, on March 08, 2022, India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc launched the MiniMed 780G system in India.

The MiniMed 780G system is a next-generation closed-loop insulin pump system for the treatment of type 1 diabetes in people aged 7 to 80 years. Leveraging the company's most advanced SmartGuard technology, the system automates the delivery of both basal insulin and correction boluses every five minutes to help people with diabetes avoid highs and lows with greater ease.

Moreover, insulin infusion pumps have greater advantages than other devices, the advancements in these pumps helps to control and manage the insulin infusions. Advanced infusion pumps offer more precise and continuous insulin delivery, which can significantly improve blood glucose control. This can lead to better long-term health outcomes and reduced complications for individuals with diabetes.

For instance, on february 14, 2023, EOFlow Co. launched its tubeless, wearable, and disposable insulin pump "EOPatch" in the UAE. It becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.

In addition, the regulatory approvals increase the trust in patients about the development of novel advanced devices. For instance, on February 16, 2022, Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, released the U.S. Food and Drug Administration (FDA) clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app. This represents the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems.

Further, the increasing prevalence of diabetes, rising FDA approvals, increasing clinical trials, increasing awareness and technological advancements in the development of novel devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the devices, the high cost of the insulin infusion pumps, technical issues associated with the devices and presence of alternative treatment options are expected to hamper the market.

Segment Analysis

The global insulin infusion pumps market is segmented based on component, application, end-user and region.

The insulin pumps segment accounted for approximately 45.3% of the insulin infusion pumps market share

The insulin pumps segment is expected to hold the largest market share over the forecast period. The increasing prevalence of diabetes is expected to increase the demand for the insulin pumps. For instance, according to the Centers for Disease Control and Prevention, 2022, 37.3 million people have diabetes.

Ongoing advancements in insulin pump technology, such as integration with continuous glucose monitoring (CGM) systems and improved user interfaces, may attract more users. Insulin pumps offer flexibility in insulin dosing, allowing users to customize their treatment plans. Their convenience, including reduced injection frequency, can make them an attractive option.

For instance, on April 25, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, released the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and technological advancements. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials, leads to the launch of novel and advanced devices in the region.

For instance, on November 15, 2022, Medtronic launched a new infusion set with a wear time of up to seven days for insulin pumps in the US. Developed in collaboration with Convatec Infusion Care, the new Medtronic Extended Infusion Set is claimed to be the first and only infusion set that is designed for double the wear time. The new infusion set leverages advanced materials to help minimize insulin preservative loss, maintain insulin flow and stability, and double the infusion set wear time.

Furthermore, the region is also known for its innovation and investment in research and development in the insulin infusion pumps. Technological advancements in North America especially in United States can lead to the introduction of cutting-edge products and solutions that attract a more users.

In addition, on July 07, 2020, Medtronic plc, the global leader in medical technology, introduced the MiniMed Mio Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps.

Competitive Landscape

The major global players in the insulin infusion pumps market include: Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, Ypsomed AG, F. Hoffmann-La Roche Ltd., Shinmyung Mediyes CO., LTD., Abbott Laboratories, SOOIL Developments Co., Ltd and Smiths Group plc, among others.

Key Developments

  • On June 21, 2023, Insulet commercially launched its Omnipod 5 automated insulin delivery system in the United Kingdom. Acton, Massachusetts-based Insulet launched Omnipod 5 insulin pumps for individuals aged two years and older with type 1 diabetes.
  • On April 21, 2023, Medtronic plc, the global leader in medical technology, cleared the U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no fingersticks while in SmartGuard technology. This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections to sugar levels every 5 minutes.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global insulin infusion pumps market. Many people with diabetes reduced their visits during the pandemic to minimize the risk of exposure to the virus. As a result, there was a decline in new pump prescriptions and fittings, impacting market growth. Healthcare providers increasingly turned to telehealth and remote monitoring solutions to provide care to individuals with diabetes. The pandemic also disrupted the supply chain of these devices globally.

Why Purchase the Report?

  • To visualize the global insulin infusion pumps market segmentation based on component, application end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of insulin infusion pumps market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global insulin infusion pumps market report would provide approximately 61 tables, 57 figures, and 188 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Component
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Advanced Insulin Infusion Pumps
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with the Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Component

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 7.1.2. Market Attractiveness Index, By Component
  • 7.2. Insulin Pumps*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Infusion Sets
  • 7.4. Reservoirs

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Type I Diabetes*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Type II Diabetes

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Home Care Settings
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Insulet Corporation
  • 12.3. Tandem Diabetes Care, Inc.
  • 12.4. Ascensia Diabetes Care Holdings AG
  • 12.5. Ypsomed AG
  • 12.6. F. Hoffmann-La Roche Ltd.
  • 12.7. Shinmyung Mediyes CO., LTD.
  • 12.8. Abbott Laboratories
  • 12.9. SOOIL Developments Co., Ltd
  • 12.10. Smiths Group plc

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us